VivoSim's NAMkind™ Data at EUROTOX Shows Superior Liver and GI Toxicity Prediction for ADCs
VIVS sits 17% above its 52-week low of $0.263 on light trading volume (0.1× avg).
Summary
VivoSim presented new EUROTOX 2026 data showing its NAMkind™ 3D human liver and intestinal platforms can predict drug toxicity across small molecules and ADCs. The data includes long-term repeat-dose modeling and mechanistic GI barrier profiling, with specific findings that NAMkind™ Liver ranked trastuzumab deruxtecan as significantly more hepatotoxic than trastuzumab emtansine, and NAMkind™ Intestine detected mucosal barrier deterioration before overt cytotoxicity. This builds on the June 29 announcement of over 90% sensitivity, adding new validation for complex modalities. The company is under Nasdaq delisting pressure and has a going concern warning, so this data is a positive step in its commercial thesis, but revenue remains minimal at $0.13M in FY2026. The presentation could support future partnerships or regulatory adoption, but no specific upcoming event is named.
At the time of this announcement, VIVS was trading at $0.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.26 to $5.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.